細(xì)胞治療使用的 lonza 04-418Q 無血清培養(yǎng)基 （點擊標(biāo)題進入）

干細(xì)胞治療使用的 lonza 12-725F 無血清培養(yǎng)基 （點擊標(biāo)題進入）

lonza 無血清培養(yǎng)基   （點擊標(biāo)題進入）  

    基因修飾T細(xì)胞因可幫助人體免疫系統(tǒng)識別并攻擊腫瘤，為此被稱為腫瘤治療的"第五支柱"。

    上述治療方法已經(jīng)在血癌，如白血病中顯示出治療功效。在某些腫瘤類型如間皮瘤治療過程中，當(dāng)這些“修修補補”的T細(xì)胞被再注入到患者血液中時，患者腫瘤會很好抵抗T細(xì)胞攻擊。

    研究人員試圖直接向腫瘤區(qū)域提供基因修飾后的T細(xì)胞，并發(fā)現(xiàn)這些T細(xì)胞不僅攻擊了癌細(xì)胞，同時成功阻斷了癌癥再次發(fā)生。他們的研究結(jié)果發(fā)表在Science Translational Medicine雜志上。

    該研究主要使用人源T細(xì)胞和小鼠腫瘤，其研究結(jié)果有助于加快開展1期臨床試驗。研究人員嘗試了兩種靜脈注射，將重新裝備（基因修飾）的T細(xì)胞注射入間皮瘤小鼠胸膜腔。奇怪的是，當(dāng)基因修飾的T細(xì)胞到達腫瘤部位，它們能“看到”敵人（癌細(xì)胞），激活自己的同時也激活其他T細(xì)胞。

     十多年來，研究人員已經(jīng)嘗試了基因改變T細(xì)胞使其產(chǎn)生受體，以匹配腫瘤細(xì)胞的抗原。上個月，研究人員在費城兒童醫(yī)院報道，當(dāng)患者的T細(xì)胞進行基因修飾并重新引入患者體內(nèi)后，30名晚期復(fù)發(fā)的白血病患者中有27名患者經(jīng)歷緩解期。

原文鏈接地址：

http://news.bioon.com/article/6661953.html

英文版

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Adusumilli PS,et al.

Translating the recent success of chimeric antigen receptor (CAR) T cell therapy for hematological malignancies to solid tumors will necessitate overcoming several obstacles, including inefficient T cell tumor infiltration and insufficient functional persistence. Taking advantage of an orthotopic model that faithfully mimics human pleural malignancy, we evaluated two routes of administration of mesothelin-targeted T cells using the M28z CAR. We found that intrapleurally administered CAR T cells vastly outperformed systemically infused T cells, requiring 30-fold fewer M28z T cells to induce long-term complete remissions. After intrapleural T cell administration, prompt in vivo antigen-induced T cell activation allowed robust CAR T cell expansion and effector differentiation, resulting in enhanced antitumor efficacy and functional T cell persistence for 200 days. Regional T cell administration also promoted efficient elimination of extrathoracic tumor sites. This therapeutic efficacy was dependent on early CD4(+) T cell activation associated with a higher intratumoral CD4/CD8 cell ratios and CD28-dependent CD4(+) T cell-mediated cytotoxicity. In contrast, intravenously delivered CAR T cells, even when accumulated at equivalent numbers in the pleural tumor, did not achieve comparable activation, tumor eradication, or persistence. The ability of intrapleurally administered T cells to circulate and persist supports the concept of delivering optimal CAR T cell therapy through "regional distribution centers." On the basis of these results, we are opening a phase 1 clinical trial to evaluate the safety of intrapleural administration of mesothelin-targeted CAR T cells in patients with primary or secondary pleural malignancies.

細(xì)胞治療使用的 lonza 04-418Q 無血清培養(yǎng)基 （點擊標(biāo)題進入）

購買進口儀器、試劑和耗材——就在始于2001年的畢特博生物 www.gducity.com